癌症耐药(英文)最新文献_第10页

The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer. DNA损伤反应在克服卵巢癌治疗耐药中的作用。

癌症耐药(英文) Pub Date : 2023-01-01 DOI: 10.20517/cdr.2022.146

Sara Bouberhan, Liron Bar-Peled, Yusuke Matoba, Varvara Mazina, Lauren Philp, Bo R Rueda

引用次数: 1

Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment. 骨髓微环境中残留的AML细胞对能量代谢靶向治疗的抵抗。

癌症耐药(英文) Pub Date : 2023-01-01 DOI: 10.20517/cdr.2022.133

Yoko Tabe, Marina Konopleva

{"title":"Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment.","authors":"Yoko Tabe, Marina Konopleva","doi":"10.20517/cdr.2022.133","DOIUrl":"https://doi.org/10.20517/cdr.2022.133","url":null,"abstract":"In response to the changing availability of nutrients and oxygen in the bone marrow microenvironment, acute myeloid leukemia (AML) cells continuously adjust their metabolic state. To meet the biochemical demands of their increased proliferation, AML cells strongly depend on mitochondrial oxidative phosphorylation (OXPHOS). Recent data indicate that a subset of AML cells remains quiescent and survives through metabolic activation of fatty acid oxidation (FAO), which causes uncoupling of mitochondrial OXPHOS and facilitates chemoresistance. For targeting these metabolic vulnerabilities of AML cells, inhibitors of OXPHOS and FAO have been developed and investigated for their therapeutic potential. Recent experimental and clinical evidence has revealed that drug-resistant AML cells and leukemic stem cells rewire metabolic pathways through interaction with BM stromal cells, enabling them to acquire resistance against OXPHOS and FAO inhibitors. These acquired resistance mechanisms compensate for the metabolic targeting by inhibitors. Several chemotherapy/targeted therapy regimens in combination with OXPHOS and FAO inhibitors are under development to target these compensatory pathways.","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"6 1","pages":"138-150"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9310600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma. 头颈部鳞状细胞癌中肿瘤干细胞耐药的机制。

癌症耐药(英文) Pub Date : 2023-01-01 DOI: 10.20517/cdr.2022.107

Juliana Mota Siqueira, Daniele Heguedusch, Camila Oliveira Rodini, Fabio Daumas Nunes, Maria Fernanda Setúbal Destro Rodrigues

{"title":"Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma.","authors":"Juliana Mota Siqueira, Daniele Heguedusch, Camila Oliveira Rodini, Fabio Daumas Nunes, Maria Fernanda Setúbal Destro Rodrigues","doi":"10.20517/cdr.2022.107","DOIUrl":"https://doi.org/10.20517/cdr.2022.107","url":null,"abstract":"Despite scientific advances in the Oncology field, cancer remains a leading cause of death worldwide. Molecular and cellular heterogeneity of head and neck squamous cell carcinoma (HNSCC) is a significant contributor to the unpredictability of the clinical response and failure in cancer treatment. Cancer stem cells (CSCs) are recognized as a subpopulation of tumor cells that can drive and maintain tumorigenesis and metastasis, leading to poor prognosis in different types of cancer. CSCs exhibit a high level of plasticity, quickly adapting to the tumor microenvironment changes, and are intrinsically resistant to current chemo and radiotherapies. The mechanisms of CSC-mediated therapy resistance are not fully understood. However, they include different strategies used by CSCs to overcome challenges imposed by treatment, such as activation of DNA repair system, anti-apoptotic mechanisms, acquisition of quiescent state and Epithelial-mesenchymal transition, increased drug efflux capacity, hypoxic environment, protection by the CSC niche, overexpression of stemness related genes, and immune surveillance. Complete elimination of CSCs seems to be the main target for achieving tumor control and improving overall survival for cancer patients. This review will focus on the multi-factorial mechanisms by which CSCs are resistant to radiotherapy and chemotherapy in HNSCC, supporting the use of possible strategies to overcome therapy failure.","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"6 1","pages":"116-137"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9310604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Mitochondria in colorectal cancer stem cells - a target in drug resistance. 结直肠癌干细胞中的线粒体-耐药性的靶标。

癌症耐药(英文) Pub Date : 2023-01-01 DOI: 10.20517/cdr.2022.116

Mateus de Almeida Rainho, Priscyanne Barreto Siqueira, Ísis Salviano Soares de Amorim, Andre Luiz Mencalha, Alessandra Alves Thole

{"title":"Mitochondria in colorectal cancer stem cells - a target in drug resistance.","authors":"Mateus de Almeida Rainho, Priscyanne Barreto Siqueira, Ísis Salviano Soares de Amorim, Andre Luiz Mencalha, Alessandra Alves Thole","doi":"10.20517/cdr.2022.116","DOIUrl":"https://doi.org/10.20517/cdr.2022.116","url":null,"abstract":"Colorectal cancer (CRC) is the third most diagnosed cancer and the second most deadly type of cancer worldwide. In late diagnosis, CRC can resist therapy regimens in which cancer stem cells (CSCs) are intimately related. CSCs are a subpopulation of tumor cells responsible for tumor initiation and maintenance, metastasis, and resistance to conventional treatments. In this scenario, colorectal cancer stem cells (CCSCs) are considered an important key for therapeutic failure and resistance. In its turn, mitochondria is an organelle involved in many mechanisms in cancer, including chemoresistance of cytotoxic drugs due to alterations in mitochondrial metabolism, apoptosis, dynamics, and mitophagy. Therefore, it is crucial to understand the mitochondrial role in CCSCs regarding CRC drug resistance. It has been shown that enhanced anti-apoptotic protein expression, mitophagy rate, and addiction to oxidative phosphorylation are the major strategies developed by CCSCs to avoid drug insults. Thus, new mitochondria-targeted drug approaches must be explored to mitigate CRC chemoresistance via the ablation of CCSCs.","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"6 2","pages":"273-283"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9816626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma. 对转移性透明细胞肾细胞癌免疫治疗耐药机制的研究。

癌症耐药(英文) Pub Date : 2023-01-01 DOI: 10.20517/cdr.2023.09

Monica Sheila Chatwal, Jad Chahoud, Philippe E Spiess

{"title":"Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma.","authors":"Monica Sheila Chatwal, Jad Chahoud, Philippe E Spiess","doi":"10.20517/cdr.2023.09","DOIUrl":"https://doi.org/10.20517/cdr.2023.09","url":null,"abstract":"Renal-cell carcinoma (RCC) remains a leading cause of cancer-related mortality worldwide. Though newer therapeutic combinations of immune checkpoint inhibitors and targeted therapies have greatly improved outcomes, resistance to these therapies is becoming a challenge for long-term control. Mechanisms of resistance have been explored in a variety of solid tumors, including RCC. Based upon our review of the current literature on the mechanisms of resistance to immunotherapies for the management of metastatic clear-cell renal cell carcinomas (mccRCC), the ensuing conclusions have been made: The management of mccRCC has progressed substantially with the advent of checkpoint inhibitors and targeted oral therapies, alone and/or in combination. Nevertheless, innate or developed resistance to these therapies remains an ongoing challenge, particularly to immune checkpoint inhibitors (ICIs). Several of the known mechanisms of resistance have been well defined, but recent progression in cellular therapies helps to expand the armamentarium of potential combination options that may overcome these modes of resistance and improve long-term disease control and survival for an otherwise dismal disease. In the ensuing review and update of the literature on the mechanisms of resistance to immunotherapies in mccRCC, we have revisited the known resistance mechanisms of immunotherapies in metastatic clear-cell RCC and explored ongoing and future strategies to overcome them.","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"6 2","pages":"314-326"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer. 重塑肿瘤微环境克服hpv阴性头颈癌的治疗耐药。

癌症耐药(英文) Pub Date : 2023-01-01 DOI: 10.20517/cdr.2022.141

Sergi Benavente

引用次数: 1

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma. 免疫检查点抑制剂治疗胰腺导管腺癌的主要障碍。

癌症耐药(英文) Pub Date : 2023-01-01 DOI: 10.20517/cdr.2022.142

Liia Akhuba, Zhanna Tigai, Dmitrii Shek

引用次数: 0

Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system. 纳米载体给药系统攻克癌症耐药途径的最新进展。

癌症耐药(英文) Pub Date : 2023-01-01 DOI: 10.20517/cdr.2023.16

Xiangyu Sun, Ping Zhao, Jierou Lin, Kun Chen, Jianliang Shen

{"title":"Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system.","authors":"Xiangyu Sun, Ping Zhao, Jierou Lin, Kun Chen, Jianliang Shen","doi":"10.20517/cdr.2023.16","DOIUrl":"https://doi.org/10.20517/cdr.2023.16","url":null,"abstract":"Cancer is currently one of the most intractable diseases causing human death. Although the prognosis of tumor patients has been improved to a certain extent through various modern treatment methods, multidrug resistance (MDR) of tumor cells is still a major problem leading to clinical treatment failure. Chemotherapy resistance refers to the resistance of tumor cells and/or tissues to a drug, usually inherent or developed during treatment. Therefore, an urgent need to research the ideal drug delivery system to overcome the shortcoming of traditional chemotherapy. The rapid development of nanotechnology has brought us new enlightenments to solve this problem. The novel nanocarrier provides a considerably effective treatment to overcome the limitations of chemotherapy or other drugs resulting from systemic side effects such as resistance, high toxicity, lack of targeting, and off-target. Herein, we introduce several tumor MDR mechanisms and discuss novel nanoparticle technology applied to surmount cancer drug resistance. Nanomaterials contain liposomes, polymer conjugates, micelles, dendrimers, carbon-based, metal nanoparticles, and nucleotides which can be used to deliver chemotherapeutic drugs, photosensitizers, and small interfering RNA (siRNA). This review aims to elucidate the advantages of nanomedicine in overcoming cancer drug resistance and discuss the latest developments.","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"6 2","pages":"390-415"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9816631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors. 肾癌耐药的机制和临床意义:免疫检查点抑制剂的叙述性回顾。

癌症耐药(英文) Pub Date : 2023-01-01 DOI: 10.20517/cdr.2023.02

Sunil Samnani, Faraz Sachedina, Mehul Gupta, Edward Guo, Vishal Navani

引用次数: 0

Concomitant medications and circulating tumor cells: friends or foes? 伴随用药与循环肿瘤细胞:是友是敌?

癌症耐药(英文) Pub Date : 2023-01-01 DOI: 10.20517/cdr.2022.68

Serena Di Cosimo, Vera Cappelletti

{"title":"Concomitant medications and circulating tumor cells: friends or foes?","authors":"Serena Di Cosimo, Vera Cappelletti","doi":"10.20517/cdr.2022.68","DOIUrl":"https://doi.org/10.20517/cdr.2022.68","url":null,"abstract":"The use of concomitant medications by patients with cancer is observed almost globally; however, little attention has been paid to this topic in the medical literature. Most clinical studies do not describe the type and duration of drugs used at the time of inclusion and during treatment or how these drugs may affect the experimental and/or standard therapy. Even less information has been published on the potential interaction between concomitant medications and tumor biomarkers. However, we do know that concomitant drugs can complicate cancer clinical trials and biomarker development, thus contributing to their interaction, leading to side effects, and resulting in suboptimal adherence to anticancer treatment. On the basis of these premises and moving from the study by Jurisova et al., which reported the effect of commonly used drugs on the prognosis of women with breast cancer and the detection of circulating tumor cells (CTCs), we comment on the role of CTCs as an emerging diagnostic and prognostic tool for breast cancer. We also report the known and hypothesized mechanisms of CTC interplay with other tumor and blood components, possibly modulated by widespread drugs, including over-the-counter compounds, and discuss the possible implications of commonly used concomitant medications on CTC detection and clearance. After considering all these points, it is conceivable that concomitant drugs are not necessarily a problem, but on the contrary, their virtuous mechanisms can be exploited to reduce tumor spread and enhance the effect of anticancer therapies.","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"6 1","pages":"30-34"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9310602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0